ARMO BioSciences Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.6B

ARMO BioSciences General Information

Description

Operator of an immuno-oncology company that is developing a pipeline of products that activate the immune system of cancer patients to recognize and eradicate tumors. The company's lead product candidate, AM0010 (pegilodecakin), stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells, which recognize and kill cancer cells and an increased presence of intra-tumoral. In addition, the company is developing a robust immuno-oncology pipeline that includes validated product candidates such as an anti-PD-1 monoclonal antibody, aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies.

Contact Information

Website
www.armobio.com
Formerly Known As
Targenics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 575 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 575 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ARMO BioSciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 22-Jun-2018 $1.6B Completed Generating Revenue
5. IPO 26-Jan-2018 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C1) 29-Aug-2017 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 10-Feb-2016 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 28-May-2014 $30M $50M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 20-Dec-2012 $20M $20M Completed Startup
To view ARMO BioSciences’s complete valuation and funding history, request access »

ARMO BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1
Series C
Series B1
Series B
Series A1 3,170,176 $0.000100 $0.02 $0.25 $0.25 1x $0.25 2.7%
Series A 19,503,817 $0.000100 $0.08 $1 $1 1x $1 16.6%
To view ARMO BioSciences’s complete cap table history, request access »

ARMO BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an immuno-oncology company that is developing a pipeline of products that activate the immune system of canc
Drug Discovery
Redwood City, CA
21 As of 2018

Houston, TX
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ARMO BioSciences Competitors (84)

One of ARMO BioSciences’s 84 competitors is Marker Therapeutics, a Formerly VC-backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marker Therapeutics Formerly VC-backed Houston, TX
Iovance Biotherapeutics Corporation San Carlos, CA
Adicet Bio Formerly VC-backed Boston, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Unicyte Venture Capital-Backed Oberdorf, Switzerland
You’re viewing 5 of 84 competitors. Get the full list »

ARMO BioSciences Patents

ARMO BioSciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3810189-A1 Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy Pending 19-Jun-2018
US-20210347842-A1 Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy Inactive 19-Jun-2018
US-20260356902-A1 Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy Pending 19-Jun-2018
WO-2019245817-A1 Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy Inactive 19-Jun-2018
JP-2022081545-A Composition and method of use of interleukin-10 in combination with an immune checkpoint pathway inhibitor Pending 10-Nov-2017 A61K38/2066
To view ARMO BioSciences’s complete patent history, request access »

ARMO BioSciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ARMO BioSciences Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
Celgene Corporation Minority
Clough Capital Partners Hedge Fund Minority
Decheng Capital Venture Capital Minority
Duff Ackerman & Goodrich PE/Buyout Minority
You’re viewing 5 of 19 investors. Get the full list »

ARMO BioSciences Acquisitions (2)

ARMO BioSciences’s most recent deal was a Merger/Acquisition with ACIR BioSciences. The deal was made on 01-Oct-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ACIR BioSciences 01-Oct-2015 Merger/Acquisition Drug Discovery
Renovo Group (Prevascar Operations) 24-Jan-2013 Merger/Acquisition Drug Discovery
To view ARMO BioSciences’s complete acquisitions history, request access »

ARMO BioSciences FAQs

  • When was ARMO BioSciences founded?

    ARMO BioSciences was founded in 2012.

  • Where is ARMO BioSciences headquartered?

    ARMO BioSciences is headquartered in Redwood City, CA.

  • What is the size of ARMO BioSciences?

    ARMO BioSciences has 21 total employees.

  • What industry is ARMO BioSciences in?

    ARMO BioSciences’s primary industry is Drug Discovery.

  • Is ARMO BioSciences a private or public company?

    ARMO BioSciences is a Private company.

  • What is the current valuation of ARMO BioSciences?

    The current valuation of ARMO BioSciences is .

  • What is ARMO BioSciences’s current revenue?

    The current revenue for ARMO BioSciences is .

  • How much funding has ARMO BioSciences raised over time?

    ARMO BioSciences has raised $295M.

  • Who are ARMO BioSciences’s investors?

    Aisling Capital, Celgene, Clough Capital Partners, Decheng Capital, and Duff Ackerman & Goodrich are 5 of 19 investors who have invested in ARMO BioSciences.

  • Who are ARMO BioSciences’s competitors?

    Marker Therapeutics, Iovance Biotherapeutics, Adicet Bio, Adaptimmune Therapeutics, and Unicyte are some of the 84 competitors of ARMO BioSciences.

  • When was ARMO BioSciences acquired?

    ARMO BioSciences was acquired on 22-Jun-2018.

  • Who acquired ARMO BioSciences?

    ARMO BioSciences was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process